ABSTRACT
BACKGROUND: Multiple organ failure (MOF) is the key determinant of mortality in acute pancreatitis (AP). Mesenteric lymph cytotoxicity contributes to organ failure in experimental models of systemic inflammation. The aim of this study was to evaluate the mesenteric lymph pathway and the lymph injury proteome in experimental AP-associated MOF, and to test the hypothesis that immunoregulatory tryptophan catabolites contribute to mesenteric lymph cytotoxicity. METHODS: Using an experimental model of AP in rats, the humoral component of mesenteric lymph in AP was compared with that from sham-operated control animals, using in vitro and in vivo cytotoxicity assays, high-throughput proteomics and high-performance liquid chromatography. The experimental findings were corroborated in a cohort of 34 patients with AP. RESULTS: Compared with biologically inactive lymph from sham-operated rats, mesenteric lymph in AP became cytotoxic 3 h after induction. Hierarchical clustering of lymph proteomic mass spectra predicted the biological behaviour of lymph. Levels of the immunoregulatory tryptophan catabolite, 3-hydroxykynurenine, were increased in cytotoxic lymph and re-created cytotoxicity in vitro. In humans with AP, plasma kynurenine concentrations correlated in real time with MOF scores and preceded a requirement for mechanical ventilation and haemodialysis. CONCLUSION: These results support the concept that mesenteric lymph-borne kynurenines may contribute to pancreatitis-associated MOF.
Subject(s)
Lymph/metabolism , Mesentery/metabolism , Multiple Organ Failure/complications , Pancreatitis/complications , Tryptophan/metabolism , Acute Disease , Animals , Kynurenine/metabolism , Ligation , Male , Neutrophils/metabolism , Proteome/metabolism , Rats , Rats, Sprague-Dawley , Respiratory BurstABSTRACT
An antagonist of cellular adhesion and motility, acetyl-C-[S-Acm]-VIGYSGDRC-[S-Acm]-NH(2) (mEGF(33-42)), shares homology with the agonist sequence CDPGYIGSR-NH(2). It has been proposed that the latter peptide binds to the high affinity 67 kDa laminin receptor. Both peptides have equal affinities for the receptor and similar conformations have been derived for both. We have examined the importance of individual non-homologous residues with respect to receptor binding and antagonistic properties of mEGF(33-42). Alanine scanning of non-conserved residues in the N-terminal half of mEGF(33-42) caused loss of biological activity with respect to cell attachment, receptor binding and migratory response. Substitution of alanine for serine (position 6) caused loss of laminin-specific cell attachment and receptor binding activities. However, the peptide did stimulate migration suggesting that this peptide may be a non-specific stimulator of migration. In contrast, alanine substitution for the C-terminal Cys-S-Acm had no apparent effect on the attachment or receptor binding activities of the peptide but generated an agonist from the antagonist parent. Comparison of the modelled folds of the alanine containing peptides revealed the presence of significant helical content in those peptides capable of stimulating migration and suggests that a reduction in bulk in the N-terminal residues is not conducive to adopting a productive binding conformation.
Subject(s)
Alanine/analysis , Peptides/chemical synthesis , Receptors, Laminin/agonists , Amino Acid Sequence , Animals , Drug Design , Epidermal Growth Factor/chemistry , Laminin/chemical synthesis , Mice , Models, Molecular , Molecular Weight , Protein Binding , Protein Conformation , Protein Isoforms/chemical synthesis , Receptors, Laminin/chemistry , Structure-Activity RelationshipSubject(s)
Organic Chemicals/chemistry , Solvents/chemistry , ADAM Proteins , ADAM17 Protein , Animals , Cell Line , Cell Survival/drug effects , Interleukin-1/physiology , Lipopolysaccharides/pharmacology , Metalloendopeptidases/metabolism , Mice , Organic Chemicals/pharmacology , Solvents/pharmacology , Tumor Necrosis Factor-alpha/physiologySubject(s)
Acute-Phase Proteins , Antibodies/immunology , Carrier Proteins/immunology , Membrane Glycoproteins , Peptides/immunology , Animals , Antibodies/chemistry , Electrophoresis, Polyacrylamide Gel , Enzyme-Linked Immunosorbent Assay , Epitopes/immunology , Mice , Rats , Recombinant Proteins/immunologyABSTRACT
To identify potential selection pressures which lead to RNA sequence conservation, we examined the occurrence rates of dinucleotides in 64 single-stranded RNA virus genomes. These viruses may offer a particular insight into these pressures since their RNA-dependent RNA polymerases lack proofreading capability. This potentiates introduction of mutations into their genomes, yet unidentified selection processes conserve the genomes to a large degree. We report a strong inverse correlation between the C+G content and the occurrence of the CpG dinucleotide (r=0.71) in the RNA virus genomes, in contrast to earlier reports (Karlin et al., 1994, Journal of Virology 68, 2889-2897). We also detected significant suppression of UpA, correlating inversely with genomic U+A content. These suppressions are coupled with over-representation of the complementary pair of dinucleotides, CpA and UpG. In addition, we highlight the fact that odds ratios for dinucleotides are not independent variables, a situation apparently not widely appreciated in the literature. This led us to view the over-representation of CpA and UpG as a consequential outcome of UpA and CpG suppression in the virus genomes. Potential factors influencing these disturbances are discussed. In addition, higher than random incidence was observed for 'out-of-frame' stop codons in the viral RNA genomes, with some preferences for individual codons being exhibited by certain virus groups. The UAG codon appeared more common in the +1 frame, the UGA in the -1 frame.
Subject(s)
Codon, Terminator , Genome, Viral , RNA Viruses/genetics , RNA, Viral/genetics , Base Sequence , Genetic Variation , Molecular Sequence Data , Sequence AnalysisABSTRACT
A laminin-antagonist peptide, comprising amino acids 33-42 of murine epidermal growth factor (mEGF-(33-42)), interacts with a breast cancer- and endothelial cell-associated receptor, which is specific for the laminin B1 chain sequence, CDPGYIGSR-NH2 (Lam.B1-(925-933)), and is immunologically similar to a previously described 67-kDa laminin receptor. In whole cell receptor assays, mEGF-(33-42), Lam. B1-(925-933), and laminin all have IC50 values for displacement of 125I-laminin in the range 1-5 nM. Cell attachment to solid-phase laminin is also blocked by all three ligands, but in contrast to the receptor assays, mEGF-(33-42) or Lam.B1-(925-933), while equipotent with each other, were less effective than laminin. The concentrations of the peptides required to produce half-maximal inhibition of attachment were in the range 230-390 nM, but those for laminin were 1000-fold lower, in the range 0.2-0.3 nM. Like laminin, solid-phase mEGF-(33-42) supports cell attachment, and this ability is blocked by anti-67-kDa receptor antibodies. Modeling studies suggest that both peptides present a tyrosyl and an arginyl residue on the same face of a right-handed helical fold with elliptical cross-section.
Subject(s)
Breast Neoplasms/metabolism , Endothelium, Vascular/metabolism , Epidermal Growth Factor/metabolism , Oligopeptides/metabolism , Peptide Fragments/metabolism , Receptors, Laminin/metabolism , Amino Acid Sequence , Animals , Binding Sites , Cattle , Cell Adhesion/drug effects , Cell Line , Chick Embryo , Female , Humans , Mice , Models, Molecular , Molecular Sequence Data , Neurokinin B/analogs & derivatives , Neurokinin B/metabolism , Tumor Cells, CulturedSubject(s)
Peptides/chemistry , Peptides/metabolism , Amino Acid Sequence , Animals , Databases, Factual , Epidermal Growth Factor/chemistry , Laminin/chemistry , Magnetic Resonance Spectroscopy , Mice , Models, Molecular , Molecular Sequence Data , Peptide Fragments/chemistry , Peptide Fragments/metabolism , Protein Conformation , Protein Folding , Sequence Homology, Amino Acid , Transforming Growth Factor alpha/chemistryABSTRACT
Laminin, murine epidermal growth factor (mEGF), and the synthetic laminin peptide Lam.B1(925-933) (a linear peptide from the B1 chain of murine laminin, CDPGY1GSR-amide) all stimulate endothelial cell motility above basal rates, whereas a synthetic mEGF fragment, mEGF33-42 (a linear peptide from the C-loop of mEGF, acetyl-C-[S-Acm]-VIGYSGDR-C-[S-Acm]-amide), inhibits motility. In both human SK HEP-1 and embryonic chick endothelial cells, mEGF33-42 blocks both EGF- and laminin-stimulated locomotion of endothelial cells. In vivo, mEGF33-42 also blocks both laminin- and mEGF-induced angiogenesis in the chick. In the human cell line. Lam.B1(925-933) has an additive effect in coincubation with either laminin or mEGF, but it blocks their effects in the chick cells. Lam.B1(925-933) alone stimulates angiogenesis in the chick but blocks laminin-induced angiogenesis. Thus, mEGF33-42 acts as a general laminin antagonist, whereas Lam.B1(925-933) acts as a laminin agonist in human cells, but in chick cells it acts as a partial antagonist. We propose that the presence of an anionic group at the eighth residue of mEGF33-42 may be the source of the antagonistic effects seen with this peptide as compared with the laminin fragment. These findings have important implications in the design of human antiangiogenic agents, and also in the use of chick models in the study of human disease.
Subject(s)
Cell Movement/drug effects , Endothelium, Vascular/drug effects , Epidermal Growth Factor/pharmacology , Laminin/antagonists & inhibitors , Neovascularization, Pathologic/prevention & control , Peptide Fragments/pharmacology , Amino Acid Sequence , Animals , Cell Line , Chick Embryo , Endothelium, Vascular/cytology , Epidermal Growth Factor/antagonists & inhibitors , Epidermal Growth Factor/chemistry , Humans , Laminin/pharmacology , Molecular Sequence Data , Peptide Fragments/chemistrySubject(s)
Epidermal Growth Factor/chemistry , Epidermal Growth Factor/pharmacology , Protein Structure, Secondary , Amino Acid Sequence , Biological Assay , Cell Line , Cloning, Molecular , Epidermal Growth Factor/biosynthesis , Escherichia coli , Humans , Mutagenesis, Site-Directed , Recombinant Proteins/biosynthesis , Recombinant Proteins/chemistry , Recombinant Proteins/pharmacology , Saccharomyces cerevisiae , Structure-Activity RelationshipSubject(s)
Epidermal Growth Factor/biosynthesis , Recombinant Proteins/biosynthesis , Saccharomyces cerevisiae/growth & development , Cloning, Molecular/methods , Epidermal Growth Factor/isolation & purification , Glucose/metabolism , Glycerol/metabolism , Humans , Plasmids , Raffinose/metabolism , Recombinant Proteins/isolation & purificationSubject(s)
Intestines/physiology , Neuropeptide Y/genetics , Pancreatic Polypeptide/genetics , Phylogeny , Torpedo/genetics , Animals , Biological Evolution , Chickens/genetics , Fishes/genetics , Humans , Mammals/genetics , Models, Molecular , Neuropeptide Y/chemistry , Pancreatic Polypeptide/chemistry , Protein ConformationABSTRACT
We describe a novel assay of pre-beta high-density lipoprotein (HDL), a unique apolipoprotein A-I (apo A-I)-containing lipoprotein particle. The pre-beta and alpha lipoproteins are separated by electrophoresis in agarose and transferred onto a membrane by capillary blotting. The membrane blot is sequentially incubated with sheep anti-human apo A-I antiserum and then with a conjugate of rabbit anti-sheep immunoglobulin and horseradish peroxidase. Chemiluminescence formed by the peroxidase-catalyzed oxidation of luminol in the presence of an enhancer is captured on photographic film, and the pre-beta HDL band is quantified by transmission densitometry. The assay is calibrated with standards prepared from a reference serum diluted in 9 mol/L urea. Within-batch precision (CV) at pre-beta HDL concentrations of 22.1 and 44.3 mg/L was 7% and 4.9% respectively. Pre-beta HDL contained 1.6% (0.65-2.6%, mean and range) of total serum apo A-I in 30 normolipidemic subjects.
Subject(s)
Apolipoprotein A-I/analysis , Immunoblotting/methods , Lipoproteins, HDL/blood , Luminescent Measurements , Adult , Drug Stability , Electrophoresis, Agar Gel , Female , High-Density Lipoproteins, Pre-beta , Humans , Immunoblotting/standards , Immunoblotting/statistics & numerical data , Male , Reference ValuesABSTRACT
Potentiated conductance shows promise for monitoring the progress of both coupling and deprotection reactions in solid phase peptide synthesis using Fmoc chemistry. Sterically hindered base may be added to the aprotic polar solvents used for synthesis, this induces ionisation of acids formed in the coupling and deprotection reactions, thus giving rise to a conductance signal in the solvent. Changes in this signal allow reactions occurring at the resin to be followed with no degradation of coupling efficiency.